# IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

> **NCT06112314** · PHASE3 · RECRUITING · sponsor: **Immunocore Ltd** · enrollment: 680 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** Brenetafusp
- **DRUG:** Nivolumab
- **DRUG:** Nivolumab + Relatlimab

## Key facts

- **NCT ID:** NCT06112314
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2027-10-16
- **Final completion:** 2027-10-16
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06112314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06112314, "IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06112314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*